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Four molecules of the tumor suppressor p53
assemble to cooperatively bind proapoptotic target
genes. The structural basis for cooperativity consists
of interactions between adjacent DNA binding
domains. Mutations at the interaction interface that
compromise cooperativity were identified in cancer
patients, suggesting a requirement of cooperativity
for tumor suppression. We report on an analysis
of cooperativity mutant p53E177R mice. Apoptotic
functions of p53 triggered by DNA damage and
oncogenes were abolished in these mice, whereas
functions in cell-cycle control, senescence, meta-
bolism, and antioxidant defense were retained and
were sufficient to suppress development of sponta-
neous T cell lymphoma. Cooperativity mutant mice
are nevertheless highly cancer prone and suscepti-
ble to different oncogene-induced tumors. Our data
underscore the relevance of DNA binding coopera-
tivity for p53-dependent apoptosis and tumor sup-
pression and highlight cooperativity mutations as a
class of p53 mutations that result in a selective loss
of apoptotic functions due to an altered quaternary
structure of the p53 tetramer.INTRODUCTION
The p53 tumor-suppressor protein acts as a hub that integrates
multiple intrinsic and extrinsic signals and launches a plethora of
either cell-protective or cell-destructive programs in response to
various types of cellular stress. Strong activation of p53 after
acute genotoxic stress typically triggers cell destruction by
apoptosis, whereas upon mild DNA damage, p53 acts cell pro-
tective by preferentially inducing damage repair and survival
(Vousden and Prives, 2009). p53-dependent apoptosis serves1512 Cell Reports 3, 1512–1525, May 30, 2013 ª2013 The Authorsas a major mechanism for counteracting hematologic malig-
nancy (Schmitt et al., 2002), whereas other activities of p53,
such as cell-cycle-inhibitory and prosenescent functions, are
equally or even more relevant for suppression of other tumor
types (Brady et al., 2011). Recent studies on restoration of p53
expression in transgenic mouse tumor models demonstrated
that the spectrum of p53-triggered tumor-suppression programs
depends strongly on oncogene and tissue context. Reactivation
of thewild-type p53 protein in establishedMyc-driven B cell lym-
phomas led to tumor regression due to apoptosis (Martins et al.,
2006; Ventura et al., 2007), whereas in sarcomas and hepatic
carcinomas, p53 caused senescence-mediated cessation of
tumor growth followed by tumor clearance through the innate
immune system (Ventura et al., 2007; Xue et al., 2007). In addi-
tion, p53 has metabolic functions that regulate glucose uptake,
glycolysis, oxidative phosphorylation, and reactive oxygen spe-
cies (ROS) levels (Gottlieb and Vousden, 2010). Emerging evi-
dence suggests that thesemetabolic functions of p53 contribute
substantially to its tumor-suppressor activity and might in fact
often be sufficient to counteract tumorigenesis (Li et al., 2012).
Although a large amount of data about regulation of p53 turn-
over, transcriptional activity, posttranslational modifications,
trafficking, and interaction with other proteins has been
collected, it still remains poorly understood how p53 selects
among the different cell-destructive or cell-protective programs
to choose the mechanism that most efficiently prevents tumori-
genesis (Beckerman and Prives, 2010; Schlereth et al., 2010b).
It was recently found that the four p53 molecules that
assemble into the functional p53 tetramer engage in extensive
intermolecular interactions when bound to a p53 response
element on the DNA (Kitayner et al., 2006). Apart from the well-
characterized interaction of the C-terminal oligomerization
domains, these interactions involve the short H1 helix within
the central DNA binding domain. H1 helix interactions are main-
tained by reciprocal salt bridges between oppositely charged
glutamate (E180) and arginine (R181) residues (corresponding
to E177 and R178 in the mouse) of each p53 monomer (Fig-
ure 1A). Functionally, these salt bridges were identified as the
structural basis for the ability of p53 to bind DNA cooperatively
(Dehner et al., 2005; Schlereth et al., 2010a) and were shown to
extend the target gene spectrum of p53 to include genes with
noncanonical response elements that deviate from the
consensus binding sequence (Schlereth et al., 2010a, 2010b).
As a consequence, point mutations in codons 180 or 181 that
reduce or increase H1 helix interactions (low or high DNA binding
cooperativity mutations, respectively) modulate the transcrip-
tional output of p53 signaling. Low cooperativity resulted in
reduced binding of p53 to target promoters, in particular pro-
moters of proapoptotic genes, whereas increased cooperativity
led to excessive activation of apoptotic genes and elevated
apoptotic activity (Schlereth et al., 2010a). Thus, although non-
cooperating p53 molecules are perfectly capable of arresting
the cell cycle, induction of apoptosis requires p53 molecules to
work together, suggestive of a safeguard mechanism designed
to protect cells from careless killing through apoptosis.
Importantly, in contrast to classical hot spot mutations, coop-
erativitymutations do not affect residues that directly contact the
DNA (class I mutations), and do not cause local or global unfold-
ing of the p53 protein (class II mutations); therefore, they repre-
sent a functionally distinct class of p53 mutations (Dehner
et al., 2005). Cooperativity-reducing mutations in codons 180
and 181 were detected in both sporadic tumors and in the germ-
line of Li-Fraumeni patients who suffer from increased cancer
susceptibility, suggesting that cooperativity is crucial for tumor
suppression by p53. In this study we engineered the cooperativ-
ity-reducing mutation p53E177R in the mouse germline to explore
the in vivo relevance of DNA binding cooperativity for tumor
suppression.
RESULTS
Generation of Germline Cooperativity Mutant p53E177R
Mice
In order to investigate the role of DNA binding cooperativity
in vivo, we generated a mouse with the cooperativity-reducing
point mutation p53E177R in the endogenous Trp53 allele (Fig-
ure 1B). p53E177R is equivalent to human p53E180R and results
in the replacement of negatively charged glutamic acid with
positively charged arginine at codon 177. Mouse embryonic
stem cells (ESCs) were electroporated with a targeting construct
bearing the p53E177R mutation together with a puromycin resis-
tance marker and a transcriptional stop sequence, flanked by
loxP sites (lox-stop-lox [LSL] cassette; Olive et al., 2004). The
LSL cassette introduced into the first intron allows conditional
expression of the knockin allele by preventing p53 expression
before Cre-mediated recombination occurs. After selection,
resistant clones were tested for correct targeting by Southern
blot (Figure 1C) and positive clones were injected into blasto-
cysts. Chimeric animals were bred for germline transmission,
which was confirmed by PCR genotyping using DNA isolated
from tail tips (Figure 1D, upper panel). The presence of the point
mutation was confirmed by sequencing (Figure 1E). The hetero-
zygous F1 animals were mated with Prm1-Cre transgenic mice
to remove the LSL cassette and generate the Trp53E177R allele.
Excision of the LSL cassette was confirmed by PCR with
tail-tip DNA (Figure 1D, lower panel). Hereafter, this allele
is called RR to denote mutation of the H1 helix sequenceCfrom 177E;178R (ER, wild-type) to 177R;178R (RR, knockin).
p53+/RR heterozygotes were intercrossed to obtain homozygous
p53RR/RR animals, which were born at Mendelian ratio and had
no growth retardation or obvious developmental defects (data
not shown). Heterozygous Trp53LSL-E177R mice (called LSL-RR,
representing a p53 null allele) were intercrossed to homozygosity
to obtain a control cohort of p53-deficient mice (p53/).
Cooperativity Mutant Mice Are Cancer Prone
To elucidate the role of DNA binding cooperativity in tumor
suppression, we generated cohorts of mice with different p53
genotypes and monitored the animals for spontaneous tumor
formation (Figure 1F). In compliance with published data (Done-
hower et al., 1992; Jacks et al., 1994), p53/mice showed early
spontaneous tumorigenesis with a median survival of 131 days.
Importantly, p53RR/RR mice were tumor prone, with a median
overall survival of 361 days, whereas the lifespan of the p53+/+
littermates exceeded 770 days. The heterozygous p53+/ and
p53+/RR animals showed an intermediate lifespan of 438 and
587 days, respectively. Furthermore, p53/RR mice with only
one functional p53 knockin allele demonstrated a significantly
shortened median survival (274 days). Taken together, these
data clearly demonstrate that reduced DNA binding cooperativ-
ity compromises the ability of p53 to suppress spontaneous
tumorigenesis.
Histopathology of the tumors showed that the tumor spectrum
varied substantially among the different p53 genotypes. In line
with literature data, 90% of p53/ mice developed lym-
phomas, which were predominantly of T cell origin (77%
B220CD3+), and only a few animals died from other tumors
(e.g., teratocarcinomas; Figures 1G and 1H; Jacks et al., 1994).
Interestingly, the percentage of hematological malignancy was
markedly lower in the p53RR/RR cohort (59%), and only 30% of
these neoplasias were B220CD3+ and therefore diagnosed as
T cell lymphoma (Figures 1G and 1H). Moreover, we frequently
observed nonmalignant spleen hyperplasia in p53RR/RR mice,
which was not the case for p53/ animals (Figure 1I). Nonmalig-
nant neoplasia was also rare in p53+/ and p53/RR animals,
whereas in p53+/RR mice, benign tumors were detected in 47%
of cases (Figure 1I). We conclude that cooperativity mutants of
p53 are less efficient in suppressing spontaneous tumorigenesis
than wild-type p53 mice, resulting in substantial cancer suscep-
tibility. However, compared with the p53 null allele, the cooper-
ativity mutant p53 still provides a residual barrier against tumor
development, protects against T cell lymphoma, and counter-
acts the transition from benign to malignant tumors.
Apoptosis Deficiency in Cooperativity Mutant Mice
Because DNA binding cooperativity was shown to be essential
for transactivation of proapoptotic genes upon enforced
expression of p53 in cell lines (Schlereth et al., 2010a), we
expected to find apoptosis defects in p53RR/RR animals. When
p53+/+, p53/, and p53RR/RR mice were exposed to whole-
body g irradiation (g-IR), the acute DNA damage induced
massive apoptosis in radiosensitive tissues of p53+/+ animals,
whereas p53/ mice were apoptosis resistant as expected.
In the thymus, developing cerebellum, and intestinal crypts of
p53RR/RR animals, apoptosis levels were similarly low as inell Reports 3, 1512–1525, May 30, 2013 ª2013 The Authors 1513
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Figure 1. Generation of the p53E177R Cooperativity Mutant Allele and Spontaneous Tumorigenesis
(A) Schematic representation of the p53 tetramer bound to DNA. Magnified views illustrate the H1 helix interactions in the p53 wild-type and p53E177R mutant.
H1 helices are highlighted in cyan; Glu180 and Arg181 are labeled.
(B) Targeting strategy. Asterisks mark the p53E177R point mutation in exon 5.
(C) Identification of ESC clones with targeted integration of the p53E177R construct by Southern blot. The 14 kb fragment corresponds to the wild-type, and the
10 kb fragment corresponds to the targeted Trp53 allele.
(D) PCR amplification of conditional mutant alleles results in a 270 bpmutant product and a 166 bp control product. PCRprimers flanking the site of recombination
yield a 290 bp wild-type band and a 330 bp mutant p53 band.
(legend continued on next page)
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p53 null mice 8 hr after IR (Figures 2A–2C).Moreover, excluding a
simple delay, we observed no significant increase in the number
of TUNEL-positive cells in intestinal crypts of p53RR/RR mice at
different time points after IR (Figures 2C and 2D). Furthermore,
when analyzing isolated thymocytes, which undergo a strictly
p53-dependent apoptosis upon g-IR (Clarke et al., 1993; Lowe
et al., 1993b), we found that p53RR/RR thymocytes were as
resistant to DNA-damage-induced apoptosis as the p53/
ones (Figure 2E, left panel). Importantly, treatment with cortico-
steroids (1 mM dexamethasone) efficiently induced apoptosis
in p53RR/RR thymocytes (Figure 2E, right panel), excluding p53-
unrelated defects in the apoptotic signaling cascade.
To analyze the apoptosis deficiency of p53RR/RR mice in more
detail, we sensitized mouse embryonic fibroblasts (MEFs) with
different p53 genotypes to apoptosis induction by the adeno-
viral E1A oncogene (Lowe et al., 1993a). Again, in contrast to
p53+/+ MEFs, the p53RR/RR MEFs were as resistant to DNA-
damage-induced apoptosis upon doxorubicin treatment as
the p53/ cells (Figure 2F). Likewise, no increase in caspase-
3/7 activity or caspase-3 cleavage was observed in cooperativ-
ity mutant cells after treatment, although total p53 levels and
serine 18-phosphorylation increased, indicative of normal p53
activation upon DNA damage (Figures 2F and 2G). In line with
the notion that p53-dependent apoptosis relies on the transcrip-
tional activation of proapoptotic target genes, Puma was only
induced in p53 wild-type MEFs (Figure 2G). Likewise, Puma,
Noxa, and Baxmessenger RNA (mRNA) was only strongly upre-
gulated in the thymus of irradiated p53+/+ mice (Figure 2H).
Thus, consistent with data from enforced p53 expression in
cell culture, the DNA binding cooperativity of endogenous p53
also proved essential for transcriptional activation of multiple
proapoptotic target genes and the acute apoptotic DNA dam-
age response in vivo.
Apart from DNA-damage-induced apoptosis, p53-induced
apoptosis is crucial to counteract the transforming activity of
Myc (Hermeking and Eick, 1994). To investigate whether DNA
binding cooperativity is essential for Myc-induced apoptosis,
we analyzed MEFs of different p53 genotypes for apoptosis
following activation of a tamoxifen-inducible Myc-ER allele. In
contrast to p53+/+ MEFs, the p53RR/RR MEFs and p53/ cells
were equally protected against Myc-induced apoptosis (Fig-
ure 2I). Moreover, p53RR/RR MEFs that were transduced with
Myc formed multiple foci, albeit with lower frequency than the
p53/ cells (Figure 2J), hinting at other p53-dependent mecha-
nisms that partially protect against transformation by Myc. We
conclude that the DNA binding cooperativity of p53 is essential
for apoptosis induction by Myc.
Reconstitution of DNA Binding Cooperativity Rescues
the Apoptosis Defect
The p53RR mutant carries a bulky double-positive charge at the
H1 helix that efficiently prevents H1 helix interactions and thus(E) Sequence traces from p53 wild-type and p53RR/RR tail-tip DNA.
(F) Kaplan-Meier survival curves for mice of the indicated genotypes.
(G) Tumor spectrum diagnosed by histopathology.
(H) Hematological malignancies classified according to B220 and CD3 immunos
(I) Proportion of benign hyperplasia and malignant neoplasia of the spleen.
Ccooperative DNA binding. In principle, the same is observed
for the p53EE mutant (p53R178E, human p53R181E), which is
characterized by a strong double-negative charge. Interestingly,
the combined expression of oppositely charged p53RR and
p53EE was shown to enable the formation of mixed p53
tetramers that engage in cooperative, wild-type-like H1 helix
interactions when binding to promoters of proapoptotic target
genes (Figure 3A; Schlereth et al., 2010a). To prove that the
apoptosis defect of the cooperativity mutant p53RR mouse is
indeed a result of disrupted H1 helix interactions, we investi-
gated whether apoptosis can be restored by complementation
with p53EE.
For this purpose, p53+/+, p53/, and p53RR/RR E1A-MEFs
were infected with a lentivirus that labels the transduced cells
with GFP and simultaneously allows tetracycline-inducible
expression of p53EE (Figure 3B). Expression of p53EE had no or
minimal effects on the percentage of GFP-positive p53+/+ and
p53/ MEFs, respectively (Figure 3C), in line with the notion
that p53EE has only a weak antiproliferative effect (Schlereth
et al., 2010a). In contrast, p53EE strongly reduced the percentage
of GFP-positive p53RR/RR MEFs, indicating that p53EE cooper-
ates with p53RR to exert a potent antiproliferative effect. Further-
more, p53EE strongly sensitized p53RR/RR (but not p53+/+ or
p53/) MEFs to a low dose of doxorubicin that on its own was
insufficient to induce cell death in p53 wild-type MEFs (Figures
3D–3F). Importantly, p53EE rescued expression of the proapo-
ptotic target genes Puma, Noxa, and Bax in a p53RR-dependent
manner (Figure 3G), resulting in rapid caspase-3 cleavage and
high levels of cell death (Figures 3E and 3F). We conclude that
p53EE expression completely rescues the apoptosis defect of
p53RR/RR MEFs, proving that the failure to activate the apoptosis
program is indeed a result of impaired H1 helix interactions and
therefore reduced DNA binding cooperativity.
Senescence and Cell-Cycle Arrest in Cooperativity
Mutant Mice
Besides apoptosis, p53 regulates other tumor-suppression
pathways, such as cell-cycle arrest and senescence. To test
whether these programs can be activated in p53RR/RR mice,
we analyzed the proliferation of MEFs under the standard
3T3 protocol. Primary MEFs isolated from p53RR/RR embryos
proliferated in culture slightly faster than p53+/+ cells, but
exhausted their replicative potential after six to eight passages
(Figure 4A) and expressed senescence-associated b-galac-
tosidase as a hallmark of cellular senescence similarly
to p53+/+ cells (Figure 4B). In response to doxorubicin-induced
DNA damage, the percentage of bromodeoxyuridine (BrdU)-
positive S phase cells decreased in p53RR/RR MEFs as a sign
of cell-cycle arrest (Figure 4C). Moreover, DNA damage led to
a robust transcriptional activation of p53 target genes involved
in cell-cycle arrest, such as Ccng1, Cdkn1a (known as
p21Cip1), and Sfn (14-3-3s), as well as the negative regulatortaining.
ell Reports 3, 1512–1525, May 30, 2013 ª2013 The Authors 1515
A B
E F G
control IR
spleen thymus
+/+
control IR
RR/RR
H&E H&E CC3
+/+
RR/RR
+/RR
C
8h 24h 48h 72hcontrol
+/+
−/−
RR/RR
IH
Puma
p53 pSer18
p53
cleaved
caspase 3
Cdk2
+/+ RR/RR
doxorubicin+- +- +- +-−/−
RR/RR
+/−
+/RR
+/+
%
 S
ur
vi
va
l
Time after treatment
(hours)
1
10
100
0 6 12 24 48
dexamethasone
1
10
100
0.1
−/−
−/−
+/−
0 6 12 24 48
0
2
4
6
8
10
12
+/
+
−/
−
R
R
/R
R
+/
+
R
R
/R
R
+/
+
R
R
/R
R
Puma Noxa Bax
control IR
−/
−
−/
−
−/−
R
el
at
iv
e 
S
ub
-G
1
J
control
Myc
+/+ RR/RR −/−
D
+/+ RR/RR −/−
TU
N
EL
po
si
tiv
e
ce
lls
pe
rc
ry
pt
/s
ec
tio
n
Time after IR, hours
Time after treatment
(hours)
**
**
**n.s. n.s. n.s.
0.6
0.8
1.0
0
2
4
6
8
10
+/+ −/−RR/RR+/RR
R
el
at
iv
e 
su
rv
iv
al
Fo
ld
 c
as
pa
se
 a
ct
iv
at
io
n
survival
caspase-3/7
control 7248248
3
0
1
2
IR
0
1
2
3
4
5
6 mock Myc
−/−+/+ RR/RRR
el
at
iv
e 
m
R
N
A
 e
xp
re
ss
io
n
(legend on next page)
1516 Cell Reports 3, 1512–1525, May 30, 2013 ª2013 The Authors
of p53, Mdm2 (Figures 4D and 4E). Of note, target-gene activa-
tion and cell-cycle arrest in response to DNA damage appeared
overall slightly lower in p53RR/RR than in p53+/+ cells. To gain
deeper insight into the cell-cycle functions of the p53RR mutant
in vivo, we analyzed cell proliferation in response to whole-
body g-IR (Figures 4H and 4I). Acute DNA damage showed
only weak effects on p53/ mice, but resulted in a strong
decrease in the number of proliferating cells with similar
kinetics in intestinal crypts of p53+/+ and p53RR/RR animals
(Figures 4H and 4I).
In addition to DNA-damage-induced cell-cycle arrest, p53
is also responsible for cell-cycle withdrawal in response to
other types of stress, including the expression of oncogenes
(Serrano et al., 1997). Similarly to p53+/+ MEFs, p53RR/RR
cells showed premature, oncogene-induced senescence in
response to HRasG12V (Figure 4F). In response to glucose
deprivation, p53 is activated in an AMP-activated protein
kinase (AMPK)-dependent manner and induces cell-cycle
arrest and senescence (Jones et al., 2005). When treated with
the AMPK activator 5-aminoimidazole-4-carboxamide (AICAR),
p53RR/RR cells, like the p53+/+ MEFs, arrested the cell cycle,
whereas p53/ cells continued to proliferate (Figure 4G).
Collectively, our data indicate that the cooperativity mutant is
capable of inducing cell-cycle arrest and senescence in
response to p53 activation by DNA damage, oncogenes, and
metabolic stress.
Antioxidant Metabolic Functions in Cooperativity
Mutant Mice
The incidence of T cell lymphoma was markedly reduced in
p53RR/RR mice compared with p53/ animals (Figure 1H), indi-
cating that p53RR retains functions important for suppressing
this type of tumor. Since p53RR/RR mice are apoptosis-deficient
in the thymus (Figures 2A and 2E), we investigated whether the
cell-cycle-inhibitory senescence function of p53 limits thymic
lymphoma development in p53RR/RR mice. However, we did
not find any difference in senescence-associated b-galactosi-
dase staining in thymus tissues collected from mice with
different p53 status (data not shown), suggesting that neither
p53’s apoptotic activity nor its prosenescent activity—two
responses that irreversibly remove the cell from the proliferative
population—are relevant for protecting p53RR/RR mice from
thymic lymphoma.Figure 2. Apoptosis Deficiency in Cooperativity Mutant Mice
(A) Representative TUNEL staining in the spleen and thymus of mice of the ind
bars: 25 mm.
(B) Apoptosis detected using antibodies specific for activated (cleaved) caspase
100 mm, 50 mm, and 25 mm (left to right).
(C and D) TUNEL staining in the small intestine of mice sacrificed at 8, 24, 48, and
section per mouse). Data represent mean ± SD. Scale bars: 25 mm.
(E) Viability of primary thymocytes after ex vivo g-IR (6 Gy) or dexamethasone tre
(F) Viability and caspase-3 activity of E1A-immortalized MEFs 24 hr after treatme
(G) Immunoblot analysis for the indicated proteins in E1A-immortalized MEFs 16
Two independent p53RR/RR MEF preparations are shown.
(H) Quantitative RT-PCR (qRT-PCR) analysis of the indicated mRNAs in the thymu
(mean ± SD) mRNA expression levels normalized to b-actin and untreated samp
(I) Apoptosis (detected as sub-G1 population) in primary MEFs 48 hr after Myc e
(J) Colony formation assay of primary MEFs expressing Myc.
CInterestingly, a number of recent studies have indicated that
the ability of p53 to control tumorigenesis has a more subtle
side, and in addition to eliminating the stressed cell, p53 can
also play a role in the protection and survival of cells exposed
to low, everyday levels of stress (Gottlieb and Vousden, 2010).
Much of these cell-protective functions appear to rely on p53’s
potent ability to regulate key metabolic pathways, including
oxidative phosphorylation and glycolysis, as well as several anti-
oxidant defense pathways. In particular, development of T cell
lymphoma in p53/mice was shown to be caused by increased
oxidative DNA damage resulting from the accumulation of ROS,
and could be prevented by continuous treatment with a ROS
scavenger (Sablina et al., 2005). To explore this possibility, we
analyzed ROS levels in thymocytes collected from young
p53+/+, p53/, and p53RR/RR mice at 60–80 days of age, when
lymphoma was not yet observed in p53/ animals. ROS levels
were significantly lower in the thymocytes of p53+/+ and
p53RR/RR mice than in p53/ cells (Figure 5A). Consistently,
the levels of the oxidative DNA adduct 8-hydroxy-2-deoxygua-
nosine (8-OHdG) were also markedly lower in both p53RR/RR
and p53+/+ samples than in the thymi of p53/mice (Figure 5B).
p53 target genes that have been implicated in antioxidant pro-
tection, such as Sesn1/2 (Sablina et al., 2005), Aldh4 (Yoon
et al., 2004), Gls2 (Hu et al., 2010; Suzuki et al., 2010), and
Dram1 (a p53 target gene involved in autophagy; Crighton
et al., 2006), were upregulated in a p53-dependent manner in
doxorubicin-treated p53RR/RR MEFs, albeit at lower levels than
in p53+/+ cells (Figure 5D). Although Tigar and Sco2 (p53 target
genes that have been implicated in p53 regulation of glycolysis
and oxidative phosphorylation; Bensaad et al., 2006; Matoba
et al., 2006) were not p53 regulated in MEFs under our treatment
conditions, both p53RR/RR and p53+/+ MEFs showed lower
glycolytic rates than p53/ MEFs on the basis of extracellular
acidification rate (ECAR) measurements obtained under both
basal and glucose- or oligomycin-stimulated conditions (Fig-
ure 5C). p53RR therefore retains the ability of wild-type p53 to
control glucose metabolism. Because inhibition of glycolysis
by p53 diverts glucose flux into the pentose phosphate pathway
to generate NADPH, which is needed for reduction of the ROS
scavenger glutathione (Bensaad et al., 2006), the retained meta-
bolic functions of p53RR provide an intriguing explanation for effi-
cient suppression of thymic lymphoma in the absence of
apoptosis and senescence.icated genotypes either untreated (control) or 8 hr after 6 Gy of g-IR. Scale
-3 (CC3) in the cerebellum of 5-day-old g-irradiated (6 Gy) mice. Scale bars:
72 hr after g-IR (6 Gy). TUNEL-positive cells were counted in 50 half-crypts (one
atment (1 mM). Data represent mean ± SE.
nt with 0.4 mg/ml doxorubicin. Data represent mean ± SD.
hr after treatment with 2 mg/ml doxorubicin. Cdk2 serves as a loading control.
s of mice either untreated (control) or 8 hr after 6 Gy of g-IR. Shown are relative
les. **p < 0.01, Mann-Whitney test.
xpression. Error bars indicate SD.
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Figure 3. Reconstitution of DNA Binding
Cooperativity Rescues the Apoptosis
Defect
(A) Rescue of DNA binding cooperativity by
complementation with the p53R178E (EE) mutant.
(B–E) Apoptosis rescue experiment.
(B) Schematic overview.
(C) Percentage of GFP+ cells following tet-induced
EE expression relative to noninduced controls.
(D) Percentage of GFP+ cells 12 hr following
induction of EE ± doxorubicin treatment
(0.2 mg/ml) relative to untreated cells.
(E) PI+ dead cells treated as in (D) were quantified
by fluorescence-activated cell sorting (FACS).
(F) Immunoblot analysis of lysates prepared from
E1A-immortalized MEFs transduced as indicated
with the tet-inducible FLAG-p53EE expression
construct and treated with 0.2 mg/ml doxorubicin
± 1 mg/ml doxycycline (tet) for 12 hr.
(G) qRT-PCR analysis of p53, Puma, Bax, and
Noxa mRNA expression 12 hr following treatment
with 0.4 mg/ml doxorubicin ± tet. Data were
normalized to b-actin and untreated controls.
All data are presented as mean ± SD.TumorSuppression by p53RR IsDependent onOncogene
Context
Together, our data indicate that the p53RR mutant is apoptosis
incompetent but retains other tumor-suppression activities,
such as induction of cell-cycle arrest and senescence, protection
from oxidative stress, and regulation of metabolism. Although
the nonapoptotic, antioxidant activity explains how p53RR pre-
vents thymic lymphomagenesis, we predicted that, due to its
apoptosis deficiency, p53RR might be inefficient at suppressing
tumorigenesis under conditions in which apoptosis represents1518 Cell Reports 3, 1512–1525, May 30, 2013 ª2013 The Authorsthe major barrier to tumor development.
To explore this possibility, we used a
transplantable fibrosarcoma model in
which p53-dependent apoptosis was
shown to be important for suppression
of tumor growth and chemotherapy
response (Lowe et al., 1993a, 1994). Pri-
mary MEFs isolated from p53+/+, p53/,
and p53RR/RR embryos were infected with
retroviruses bearing E1A and HRasG12V
oncogenes and after selection were in-
jected subcutaneously into immunodefi-
cient nude mice to induce fibrosarcomas.
We observed significantly increased
tumor growth from both p53/ and
p53RR/RR cells compared with p53+/+
MEFs (Figure 6A). Furthermore, in stark
contrast to p53+/+ xenografts, no increase
in apoptosis was detected in p53RR/RR
tumors after chemotherapy (Figure 6B).
Thus, apoptosis deficiency completely
abrogated the tumor-suppressor activity
of the p53RR mutant in this transplanted
fibrosarcoma model.To investigate whether p53RR can suppress tumorigenesis in
a genetically defined, nontransplanted mouse tumor model, we
used Em-Myc mice that mimic aggressive Burkitt-like B cell
lymphomas in humans (Adams et al., 1985). In Em-Myc lym-
phomas, apoptosis is considered to be essential for tumor
suppression by p53 (Michalak et al., 2008; Schmitt et al.,
2002). We generated cohorts of Em-Myc mice with different
p53 genotypes and monitored tumorigenesis in these mice.
We observed a strongly reduced survival of p53+/RR mice in
comparison with their p53+/+ littermates (Figure 6C).
Genotyping of tumor samples showed a loss of the p53 wild-
type allele in most tumor samples from p53+/ and p53+/RR
mice, indicating selection against wild-type p53 in favor of
either the p53 null or the apoptosis-deficient p53RR allele (Fig-
ure 6D). Strong nuclear p53 staining in p53/RR lymphomas in-
dicates that p53RR is expressed but is unable to counteract tu-
mor growth efficiently (Figure 6E). These data support the
notion that p53-dependent apoptosis is essential for suppres-
sion of Myc-driven B cell lymphomagenesis.
Interestingly, the median survival of p53+/RR mice was
10 days longer than that of p53+/ mice (p < 0.0001), suggest-
ing that p53RR retains residual tumor-suppressor activity that de-
lays lymphomagenesis in this model. Histological analysis of tu-
mors showed low levels of spontaneous apoptosis in all but the
p53+/+ mice and excludes a residual apoptotic activity as an
explanation (Figures 6E and 6F). However, lymphomas from
p53+/RR mice displayed high amounts of senescent cells, similar
to or higher than the amounts observed in tumors from p53+/+
animals (Figures 6E and 6F). It was previously reported that
p53-induced apoptosis of lymphoma cells can trigger macro-
phages to secrete transforming growth factor b (TGF-b) as a
critical non-cell-autonomous inducer of cellular senescence
(Reimann et al., 2010). However, both apoptosis levels and
macrophage infiltration were found to be low in lymphomas of
p53+/RR mice (Figures 6E and 6F), indicating that senescence
in these lymphomas is instead mediated by a cell-autonomous
mechanism that is directly triggered by p53 in the absence of
apoptotic functions.
In summary, the residual, nonapoptotic tumor-suppressor
activities of p53 appear sufficient to protect against tumors
such as thymic lymphoma, but p53-induced apoptosis, which
relies on cooperative DNA binding by several p53 molecules, is
indispensable for suppressing other oncogene-induced tumors.
DISCUSSION
p53 DNA binding cooperativity mutations represent a distinct
class of p53 mutations. These mutations affect interactions
between adjacent p53 DNA binding domains in the tetrameric
p53-DNA complex, but, unlike typical class I or II hot spot muta-
tions, they do not disturb folding, tetramerization, or DNA con-
tact (Dehner et al., 2005; Schlereth et al., 2010a). Nevertheless,
cooperativity mutations have been identified in sporadic tumors
and segregate with cancer susceptibility in Li-Fraumeni syn-
drome families, which implies a central role for p53 DNA binding
cooperativity in tumor suppression (Schlereth et al., 2010a).
Here, we provide unequivocal genetic in vivo evidence support-
ing this notion.
We observed a strikingly increased incidence of spontaneous
tumorigenesis that resulted in reduced survival in mice with
the cooperativity-reducing point mutation p53RR (Figure 1F).
Furthermore, the p53RR mutant could not suppress the growth
of oncogene-induced xenograft tumors and did not pose a sub-
stantial barrier to Myc-driven lymphomagenesis (Figure 6). Our
studies showed that the cooperativity mutation abrogated p53-
mediated transactivation of key proapoptotic target genes,
including Puma,Noxa, andBax, resulting in apoptosis resistance
in response to acute genotoxic stress or Myc overexpression.CImportantly, the apoptosis defect could be fully rescued with a
second cooperativity mutant that complemented the p53RR
mutant and restored cooperativity, thereby proving that a lack
of cooperativity is the underlying cause of apoptosis resistance.
Apoptosis-independent activities of p53, such as cell-cycle
arrest, senescence, regulation of metabolism, and antioxidant
functions, were retained in p53RR mice. Interestingly, these p53
functions were largely sufficient to protect against spontaneous
T cell lymphomas, indicating that in spite of their reduced
potency, cooperativity mutants can provide residual tumor sup-
pression depending on the tissue and oncogene context.
For a long time, elimination of damaged cells by apoptosis
seemed to be the safest way to prevent tumorigenesis, and
thus p53’s proapoptotic activity was considered to be of crucial
importance for tumor suppression (Lowe et al., 1993a, 1994).
This notion is supported by the fact that disruption of apoptosis
downstream of p53 eliminates the pressure to inactivate p53
during Myc-driven lymphomagenesis, indicating that apoptosis
is the only p53 function that is selected against (Schmitt et al.,
2002). Conversely, a mutant of p53 in the proline-rich region,
which is deficient in cell-cycle arrest functions but retains proap-
optotic activity, reduces spontaneous tumorigenesis in gene-
modified mice (Toledo et al., 2006). Similarly, mice deficient for
Cdkn1a (p21CIP1), which mediates p53-induced cell-cycle ar-
rest and contributes to the development of cellular senescence,
do not show the cancer susceptibility of p53-deficient animals
(Deng et al., 1995).
However, recent data provide evidence that apoptosis may be
dispensable for p53’s tumor-suppressor activity. The absence of
spontaneous tumors in mice lacking Puma, a p53 target gene
that is crucial for p53-mediated apoptosis in several tissues
(Jeffers et al., 2003), suggests that p53 can provide sufficient
tumor suppression in the absence of apoptosis (Michalak
et al., 2008). Apart from apoptosis, p53 is well characterized
for inducing senescence in response to persistent low-level acti-
vation of DNA damage signaling upon expression of oncogenes
such as Ras (Serrano et al., 1997). p53-triggered senescence
was also readily detected in premalignant tumors initiated by
conditional expression of oncogenic KrasG12V in mice and pro-
tected against progression to carcinomas (Collado et al.,
2005). Moreover, a number of apoptosis-deficient p53 mutants
have recently been characterized in transgenic mouse models.
For example, an apoptosis defect was reported for mice with a
mutation to proline at arginine-172, which is crucial for coordi-
nating the central zinc ion and stabilizing the overall structure
of the DNA binding domain (Liu et al., 2004). p53R172H, one of
the most common hot spot mutations, causes a global denatur-
ation of the DNA binding domain associated with complete loss
of function (Bullock and Fersht, 2001). Although it has not been
proved experimentally, the p53R172P mutation may have a
more subtle effect that selectively destabilizes the H1 helix and
thus compromises DNA binding cooperativity in amanner similar
to that observed for the p53RR mutation. Importantly, although
the p53R172P mutant is apoptosis deficient, it was shown to
suppress spontaneous tumorigenesis and maintain genomic
stability due to its intact cell-cycle arrest and senescence func-
tions (Cosme-Blanco et al., 2007; Liu et al., 2004; Van Nguyen
et al., 2007). Similarly, the transactivation-domain mutantell Reports 3, 1512–1525, May 30, 2013 ª2013 The Authors 1519
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Figure 5. Antioxidant Metabolic Functions in Cooperativity Mutant Mice
(A) ROS levels in thymocytes from 60- to 80-day-old mice assessed by flow-cytometric 5-(and-6)-chloromethyl-20,70-dichlorodihydrofluorescein diacetate (DCF)
staining normalized to p53+/+ samples. *p < 0.05; **p < 0.01 Mann-Whitney test.
(B) Detection of oxidation-induced DNA damage in thymi by measurement of 8-OHdG in genomic DNA samples. *p < 0.05, Mann-Whitney test.
(C) ECAR as ameasure of glycolytic activity measured in primaryMEFs in the absence of glucose (basal), after stimulation with 10mMglucose, and after inhibition
of aerobic respiration by oligomycin. **p < 0.005; ***p < 0.001; ****p < 0.0001, Mann-Whitney test.
(D) qRT-PCR analysis of mRNA expression levels in primary MEFs treated as indicated for 12 hr with 0.4 mg/ml doxorubicin. Data were normalized to b-actin and
untreated controls.
All data show mean ± SD. Statistical analysis: *p < 0.05; **p < 0.005; ***p < 0.001, Mann-Whitney test.p53L25Q;W26S, which is deficient for transcriptional activation of
most apoptotic and cell-cycle arrest target genes but neverthe-
less is proficient in senescence induction, suppressed KrasG12D-
driven lung tumorigenesis, indicating that full transcriptional
activity is not required for the prosenescent functions of p53Figure 4. Senescence and Cell-Cycle Arrest in Cooperativity Mutant M
(A) Proliferation potential of primary MEFs under the 3T3 protocol.
(B) Senescence-associated b-galactosidase in primary MEFs from (A). Scale bar
(C) BrdU positivity in cells treated for 12 hr with doxorubicin (0.2 mg/ml) relative t
(D) Immunoblot analysis of primary MEFs treated as indicated with 0.4 mg/ml do
preparations are shown for each genotype.
(E) qRT-PCR analysis of mRNA expression levels in primary MEFs treated as indic
untreated controls. *p < 0.05; **p < 0.01; Mann-Whitney test.
(F) Senescence-associated b-galactosidase in MEFs transduced with empty vec
(G) BrdU incorporation in primary MEFs treated with the AMPK activator AICAR
(H) BrdU staining in intestine at the indicated time points after whole-body g-IR (
(I) Quantification of BrdU+ S phase cells.
All data show mean ± SD. Scale bars represent 20 mm.
C(Brady et al., 2011). Our study of the cooperativity mutant
p53RR, which has a severely compromised DNA binding ability
and a strongly reduced target gene spectrum, provides evidence
in support of this notion. Although p53RR was unable to induce
apoptosis in response to DNA damage or oncogenes, itice
s: 25 mm.
o untreated controls.
xorubicin for 24 hr. Cdk2 serves as a loading control. Two independent MEF
ated for 12 hr with 0.4 mg/ml doxorubicin. Data were normalized to b-actin and
tor or HRasG12V.
(0.5 mM) relative to untreated controls.
6 Gy).
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established a cell-cycle arrest after DNA damage and drove
MEFs into senescence upon cell-culture stress or expression
of oncogenic Ras.
Recent data suggest that both cell-autonomous and non-cell-
autonomous senescence can be relevant for suppression of
hematologicalmalignancies. InEm-Myc;Trp53+/+mice, apoptotic
cells attract and activate macrophages to secrete TGF-b, which
induces senescence in a non-cell-autonomousmanner. Inactiva-
tion of the senescence-related histone methyltransferase
Suv39h1 abrogated cellular senescence and significantly accel-
erated lymphoma development, indicating that p53-dependent
apoptosis can trigger a tumor stroma-derived senescence
response that limits Myc-driven lymphomagenesis (Reimann
et al., 2010). In our experiments, Em-Myc-induced lymphoma-
genesis in p53+/RR mice was significantly delayed by 10 days
compared with p53+/ animals concomitantly with high levels
of senescence in the lymphoma cells (Figure 6E). However, this
occurred in the absence of elevated levels of apoptosis and
was not accompanied by recruitment of macrophages or
increased secretion of TGF-b (data not shown), suggesting that
senescent lymphoma cells in p53+/RR mice are a consequence
of the documented cell-autonomous, DNA-damage-response-
mediated, prosenescent capability ofMyc (Reimann et al., 2010).
Genome-wide transcriptional and chromatin profiling is gener-
ating a constantly growing list of p53 target genes, many of
which are not linked directly to either apoptosis or senescence.
Among them are genes that participate in the regulation of
energy metabolism, autophagy, and antioxidant defense (Got-
tlieb and Vousden, 2010). These alternative p53-dependent
pathways, which promote homeostatic stability in response to
metabolic stress such as glucose starvation or ROS exposure,
are believed to contribute substantially to tumor suppression
(Li et al., 2012). For example, p53-induction of TIGAR inhibits
glycolysis and diverts glucose flux into the pentose phosphate
pathway to increase NADPH-dependent glutathione reduction
(Bensaad et al., 2006). Furthermore, p53 directly transactivates
genes such as Sesn1 and Sesn2 (Sablina et al., 2005), Gls2
(Hu et al., 2010; Suzuki et al., 2010), and Aldh4 (Yoon et al.,
2004), all of which contribute to the antioxidant defense. In line
with the notion that p53 is a central regulator of ROSmetabolism,
loss of p53 leads to oxidative DNA damage, a major cause of
thymic lymphoma in p53/ mice (Sablina et al., 2005). The
p53RR mutant retained the ability to upregulate antioxidant
genes and inhibit glycolysis (Figure 5). This resulted in low, p53
wild-type-like ROS and oxidative DNA-damage levels in
p53RR/RR thymi and concomitantly a low incidence of thymicFigure 6. Tumor Suppression by p53RR Is Dependent on Oncogene Co
(A and B) p53RR is a poor suppressor of fibrosarcoma xenografts. Primary MEF
nude mice.
(A) Mean (±SD) weight of xenograft tumors after 2 weeks. **p < 0.001, Mann-Wh
(B) Apoptosis detected by TUNEL or cleaved caspase-3 staining treated as indic
(C–F) p53RR is a poor suppressor of Em-Myc lymphomas.
(C) Kaplan-Meier survival curves of Em-Myc mice of the indicated p53 genotypes
(D) Loss of heterozygosity (LOH) analysis by PCR genotyping of Em-Myc lympho
(E) Histological analysis for p53, markers of apoptosis (TUNEL, cleaved caspase
tosidase, H3K9me3) in representative lymphomas from mice of the indicated p5
(F) Quantification of histological analyses in (E). At least 26 sections from >10mice
scores among the samples for each p53 genotype. ***p < 0.0005; ****p < 0.0001
Clymphoma. Thus, our data support the relevance of alternative
p53-regulated effector programs, such as regulation of glucose
metabolism and ROS levels, for tumor suppression.
Considering that cooperativity mutants bind and regulate only
a limited set of all wild-type p53 target genes (Schlereth et al.,
2010a), it is surprising that the remaining small number of target
genes proved sufficient to maintain at least partially the cell-
cycle arrest, senescence, antioxidant, and metabolic functions
of p53, effectively counteract the transforming activity of Ras
(Figure 4F), and limit the spontaneous development of T cell lym-
phoma in mice (Figure 1H). Similarly, the recently reported
p533KR mutant, which eliminates three acetylation sites in the
DNA binding domain, lacks the three major p53 tumor suppres-
sor activities (apoptosis, cell-cycle arrest, and senescence) but
retains residual antioxidant and metabolic functions sufficient
to delay thymic lymphomagenesis (Li et al., 2012). Likewise,
the p5325,26 transactivation domain mutant, which is severely
compromised for transactivation of most p53 target genes,
retains the ability to induce senescence and suppress tumori-
genesis in multiple tumor models (Brady et al., 2011; Jiang
et al., 2011). Because cooperativity, acetylation, and transacti-
vation-domain mutations target different aspects of p53-medi-
ated gene regulation, the changes in p53’s target gene spectrum
are dissimilar. For example, although p533KR does not activate
Cdkn1a, Puma, Noxa, or Bax, p5325,26 and p53RR retain the abil-
ity to activate Bax and Cdkn1a, respectively. Different target
genes therefore exhibit distinct requirements for p53 acetylation,
DNA binding, and transactivation. Which specific sets of p53
target genes are the most relevant for tumor suppression in
different oncogenic and cellular signaling contexts remains to
be elucidated. It is anticipated that cooperativity mutant mice
will provide a valuable tool for such studies.
It is unknown whether DNA binding cooperativity of p53 is
regulated in vivo, but this mechanism might provide a tempting
opportunity for the development of new strategies to modulate
the p53 response to chemotherapy. ‘‘Sensitization’’ of the p53
pathways by extra genomic copies of p53 or dampening of nega-
tive regulators such asWip1 inhibits tumor growth and leads to a
cancer-resistant phenotype in mice (Demidov et al., 2007; Gar-
cı´a-Cao et al., 2002; Shreeram et al., 2006). One can suppose
that enhanced DNA binding cooperativity would sensitize cells
to oncogenic stress, thus providing protection against sponta-
neous tumorigenesis in patients with a predisposition to familial
cancer. We have shown that higher than normal cooperativity,
achieved experimentally by coexpressing the two complement-
ing cooperativity mutants p53RR and p53EE, results in cell deathntext
s were transformed with E1A and HRasG12V and injected subcutaneously into
itney test.
ated for 24 hr with 20 mg/kg doxorubicin. Scale bars: 50 mm.
. p < 0.0001 for all pairwise comparisons (log rank test).
mas. Asterisks mark lymphoma samples without LOH.
-3), macrophages (F4/80), and senescence (senescence-associated b-galac-
3 genotypes. Scale bars: 50 mm.
of each genotype were analyzed. Shown is the distribution of staining intensity
, unpaired t test.
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at doses of doxorubicin that are inefficient for killing p53
wild-type cells (Figures 3D–3F). Increasing cooperativity with
small molecules might therefore represent an attractive and
straightforward way to enhance the proapoptotic activity and
simultaneously reduce the prosurvival activity of p53. Although
they would clearly be beneficial for patients with wild-type p53,
such strategies might also prove helpful for cooperativity
mutants of p53 and possibly for reactivating the more common
p53 hot-spot mutants. However, considering conflicting reports
on premature aging as a possible consequence of increased p53
activity (Reinhardt and Schumacher, 2012), caution is warranted
because it is unknown at present what consequences an
increase in DNA binding cooperativity would have for normal
cells and in particular stem cells.
On the other hand, the extent to which the nonapoptotic func-
tions of p53 contribute to the effectiveness of treatment and
suppression of residual disease is unclear. p53-triggered senes-
cence in combination with clearance of senescent tumor cells by
the immune system might provide protection against relapse
similar to that achieved by direct killing (Xue et al., 2007),
whereas extensive apoptosis induced by aggressive cytotoxic
therapy often burdens patients with severe side effects. More-
over, there is evidence that p53-induced apoptosis might even
actively drive tumor formation, whereas mice defective in p53-
induced apoptosis due to loss of its proapoptotic target gene,
Puma, resist g-IR-induced lymphomagenesis (Labi et al.,
2010). This indicates that modulating p53 activity to reduce
apoptosis while retaining other tumor-suppression functions,
as could be achieved by reducing cooperativity, might be useful
for designing therapies with less side effects.
We believe that our data contribute to a deeper understanding
of the mechanisms that regulate p53-mediated cell-fate deci-
sions because they indicate an essential requirement of p53
cooperativity for apoptosis induction as the strongest outcome
of p53 pathway activation. The demonstrated tissue- and
context-dependent role of p53 cooperativity for tumor suppres-
sion will pave the way for designing strategies aimed at modu-
lating p53 cooperativity to fine-tune p53 activity for improved
cancer therapy.EXPERIMENTAL PROCEDURES
Generation and Characterization of Mice
For generation of the Trp53R177E knockin mouse, the targeting vector (Olive
et al., 2004) was modified to carry only the mutation CTC->GCC in exon 5 of
Trp53, resulting in a Glu->Arg substitution at codon 177. The point mutation
was introduced using the QuikChange Multi Site-Directed Mutagenesis Kit
(Stratagene) and the primer 50-GAGGTCGTGAGACGCTGCCCCCACCATC
GGCGCTGCTCCGATGG-30. The complete targeting vector was verified by
Sanger sequencing. R1 mouse ESCs (129X1/SvJ 3 129S1) were electropo-
rated with the targeting construct linearized by NotI. Selection was performed
in the presence of 2 mg/ml puromycin, and resistant clones were tested using
Southern blot with EcoRI-digested genomic DNA according to the standard
protocol. A 50 external probe and an internal probe (complementary DNA
[cDNA] from puromycin marker) were amplified by PCR and used for identifi-
cation of correctly targeted clones. Twenty out of 480 ESC clones were
confirmed to be positive for targeted integration. Twelve clones were
confirmed for the presence of the mutation by sequencing of PCR products
obtained from exons 5 and 6 using genomic DNA isolated from ESCs (primers:
F-50-TCTCTTCCAGTACTCTCCTCC-30 and R-50-AATTACAGACCTCGGGT1524 Cell Reports 3, 1512–1525, May 30, 2013 ª2013 The AuthorsGGCT-30). Germline transmission was achieved with two clones used for blas-
tocyst injection. Additional mutations were excluded by sequencing of all
exons and exon-intron boundaries in the Trp53 gene. Knockin mice were
kept on a pure 129Sv background. Prm1-Cre and Em-Mycmice were obtained
from The Jackson Laboratory. All experiments were performed in accordance
with the German Animal Welfare Act (Deutsches Tierschutzgesetz) and were
approved by the local authorities.
For further details regarding the materials and methods used in this work,
see Extended Experimental Procedures.
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